Value
7.7/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 6.4 |
| P/S | 7.8 |
| EV/EBITDA | 5.3 |
| Fwd P/E | 9.3 |
| PEG | 10.0 |
| Analyst target | 6.0 |
- ▸Forward P/E: 9.6x
- ▸PEG: 0.12
- ▸Attractively valued
INDV · Why this verdict
Why Indivior Pharmaceuticals (INDV) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.5/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company ranks in the top tier relative to sector peers on margins, and its gross and operating margin components score at the highest level — positioning it as one of the most profitable businesses in its peer group on a per-unit basis. Peer-rank breakdown | Net margins should remain above 15% for 4 consecutive quarters if the peer-superior profitability thesis remains intact. | →Stable |
| CounterFree cash flow is only 18% of net income — flagged as a red flag — meaning reported margins are not converting into cash at the expected rate; if cash conversion remains structurally weak, the apparent margin advantage is partially offset by poor earnings quality. | ||
The company has beaten analyst earnings estimates in each of its four most recent quarters with an average positive surprise of 61.5%, including surprises of 104%, 75%, 22%, and 45% from oldest to most recent — a pattern of consistent and substantial over-delivery that signals management is either guiding conservatively or that underlying business momentum is materially stronger than consensus models. Catalyst breakdown | Average earnings surprise should remain above 20% per quarter for the next four quarters if the execution thesis is intact. | →Stable |
| CounterAn average surprise of 61.5% across four quarters will almost certainly cause consensus estimates to reset substantially higher; once the analyst community recalibrates, the bar for future beats rises significantly and the magnitude of positive surprises is likely to compress even if underlying business performance remains strong. | ||
At a forward price-to-earnings ratio of 9.8x and a PEG ratio of 0.12, the stock screens as priced well below its earnings growth rate — among the cheapest valuations relative to growth in the specialty pharmaceutical peer group — with approximately 16.7% remaining to the analyst target. Valuation breakdown | The forward price-to-earnings ratio should expand above 14x over the next 12 months for the valuation re-rating thesis to have materially played out. | →Stable |
| CounterSpecialty pharmaceutical companies often trade at compressed multiples because product revenue concentration creates binary risk around patent cliffs or generic entry; a low PEG may reflect market skepticism about the durability of the earnings growth trajectory rather than a straightforward valuation opportunity. | ||
Free cash flow represents only 18% of net income, a level flagged as a red flag on earnings quality — meaning more than 80% of reported net income is not yet materializing as cash, which raises questions about whether the headline earnings trajectory is as strong as it appears. Quality breakdown | Free cash flow as a percentage of net income should rise above 50% for 2 consecutive quarters for the cash conversion concern to be resolved. | →Stable |
| CounterA temporary gap between free cash flow and net income can reflect working capital timing effects or near-term capital allocation decisions that normalize over a business cycle; a company growing as rapidly as the beat streak implies may be investing cash aggressively in growth, which would be a reasonable explanation for the gap. | ||
Short interest at 13% of float reflects a meaningful bearish contingent, and on-balance volume is in a distribution pattern — falling OBV indicates that more volume is occurring on down days than up days, suggesting that some holders are quietly exiting even as the fundamental picture looks strong. Key risks | Short interest should fall below 7% of float and on-balance volume should turn to an accumulation trend for the technical distribution headwind to be considered resolved. | →Stable |
| CounterA 13% short interest is elevated but not extreme, and distribution-phase volume readings in a stock with strong earnings momentum often reflect profit-taking rather than a fundamental reassessment; the same short interest that creates a headwind can reverse into covering support if the next earnings beat is sufficiently large. | ||
The company ranks in the top tier relative to sector peers on margins, and its gross and operating margin components score at the highest level — positioning it as one of the most profitable businesses in its peer group on a per-unit basis.
→StablePeer-rank breakdown
- Expectation
- Net margins should remain above 15% for 4 consecutive quarters if the peer-superior profitability thesis remains intact.
CounterFree cash flow is only 18% of net income — flagged as a red flag — meaning reported margins are not converting into cash at the expected rate; if cash conversion remains structurally weak, the apparent margin advantage is partially offset by poor earnings quality.
The company has beaten analyst earnings estimates in each of its four most recent quarters with an average positive surprise of 61.5%, including surprises of 104%, 75%, 22%, and 45% from oldest to most recent — a pattern of consistent and substantial over-delivery that signals management is either guiding conservatively or that underlying business momentum is materially stronger than consensus models.
→StableCatalyst breakdown
- Expectation
- Average earnings surprise should remain above 20% per quarter for the next four quarters if the execution thesis is intact.
CounterAn average surprise of 61.5% across four quarters will almost certainly cause consensus estimates to reset substantially higher; once the analyst community recalibrates, the bar for future beats rises significantly and the magnitude of positive surprises is likely to compress even if underlying business performance remains strong.
At a forward price-to-earnings ratio of 9.8x and a PEG ratio of 0.12, the stock screens as priced well below its earnings growth rate — among the cheapest valuations relative to growth in the specialty pharmaceutical peer group — with approximately 16.7% remaining to the analyst target.
→StableValuation breakdown
- Expectation
- The forward price-to-earnings ratio should expand above 14x over the next 12 months for the valuation re-rating thesis to have materially played out.
CounterSpecialty pharmaceutical companies often trade at compressed multiples because product revenue concentration creates binary risk around patent cliffs or generic entry; a low PEG may reflect market skepticism about the durability of the earnings growth trajectory rather than a straightforward valuation opportunity.
Free cash flow represents only 18% of net income, a level flagged as a red flag on earnings quality — meaning more than 80% of reported net income is not yet materializing as cash, which raises questions about whether the headline earnings trajectory is as strong as it appears.
→StableQuality breakdown
- Expectation
- Free cash flow as a percentage of net income should rise above 50% for 2 consecutive quarters for the cash conversion concern to be resolved.
CounterA temporary gap between free cash flow and net income can reflect working capital timing effects or near-term capital allocation decisions that normalize over a business cycle; a company growing as rapidly as the beat streak implies may be investing cash aggressively in growth, which would be a reasonable explanation for the gap.
Short interest at 13% of float reflects a meaningful bearish contingent, and on-balance volume is in a distribution pattern — falling OBV indicates that more volume is occurring on down days than up days, suggesting that some holders are quietly exiting even as the fundamental picture looks strong.
→StableKey risks
- Expectation
- Short interest should fall below 7% of float and on-balance volume should turn to an accumulation trend for the technical distribution headwind to be considered resolved.
CounterA 13% short interest is elevated but not extreme, and distribution-phase volume readings in a stock with strong earnings momentum often reflect profit-taking rather than a fundamental reassessment; the same short interest that creates a headwind can reverse into covering support if the next earnings beat is sufficiently large.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Indivior Pharmaceuticals has delivered four consecutive earnings beats with an average positive surprise exceeding 60%, trades at a forward price-to-earnings ratio of 9.8x with a PEG of 0.12, and carries best-in-class peer-relative margins — a combination of execution and valuation that makes the risk/reward favorable at current levels, tempered by a cash-conversion gap and 13% short interest that warrant ongoing monitoring.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 10.0 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 9.8 |
| Current ratio | 3.4 |
| FCF quality | 1.4 |
| Moat | 7.0 |
| Rule of 40 | 3.0 |
| Piotroski F | 5.6 |
- ▸Strong margins: 20%
- ▸Earnings quality RED FLAG: 18% FCF/NI
- ▸Rule of 40: 23 (fail)
Growth
8.7/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 7.3 |
| EPS growth | 10.0 |
Momentum
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 7.6 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 1.8 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.6 |
| Price target | 8.4 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (6.0) — signal dampened
- ▸Analyst upside: 28%
Insider
3.9/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.2 |
- ▸Modest insider selling — $2,064,583 (0.044% of mkt cap)
Peer rank
6.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.5 |
| quality rank | 8.5 |
| growth rank | 7.0 |
- ▸Best-in-class margins
Technical
5.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.0 |
| support resistance | 4.2 |
| 52w position | 8.6 |
Risk (lower is worse)
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.0 |
| days to cover | 3.3 |
| volatility | 3.5 |
| put call | 3.3 |
| implied vol | 0.0 |
| beta | 6.4 |
- ▸High IV: 84%
Catalyst
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLDPassed (7)
- MOMENTUM:4.9>=4.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:34d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.1<1.5@spot
Warning (1)
- MOMENTUM:4.9<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
1.05
Upside
+11.1%
Downside
10.6%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 62, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — MCap $4.7B<$5B
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:4.9>=4.5. Top dim: Growth at 8.7; weakest: Risk (lower is worse) at 3.4. No conviction either direction.
The strongest dimensions are Growth at 8.7, Value at 7.7, and Catalyst at 7.5; the weakest are Risk (lower is worse) at 3.4, Insider at 3.9, and Momentum at 4.9. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 1.05 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Perfect Four Quarter Beat Streak
Trip ifEPS surprise falls below 0% for 1 quarter, breaking the four-quarter perfect beat streak.
- P2Attractive Valuation Low Peg
Trip ifForward price-to-earnings ratio expands above 16x, signaling the valuation opportunity has substantially re-rated.
- P3Best In Class Peer Margins
Trip ifNet margin compresses below 15% for 2 consecutive quarters.
- P4Cash Conversion Quality Gap
Trip ifFree cash flow as a percentage of net income rises above 50% for 2 consecutive quarters.
- P5Short Interest Volume Headwind
Trip ifShort interest falls below 7% of float.